Who are Travoprost and Timolol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fixed combination latanoprost-timolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/travoprost-and-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Travoprost and Timolol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Travoprost and Timolol (Travoprost and Timolol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog and beta-blocker combination. Area: Ophthalmology.

marketed Prostaglandin analog and beta-blocker combination FP receptor (travoprost); beta-2 adrenergic receptor (timolol) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Travoprost and Timolol (Travoprost and Timolol) — Afyon Kocatepe University Hospital. Travoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Travoprost and Timolol TARGET	Travoprost and Timolol	Afyon Kocatepe University Hospital	marketed	Prostaglandin analog and beta-blocker combination	FP receptor (travoprost); beta-2 adrenergic receptor (timolol)
fixed combination latanoprost-timolol	fixed combination latanoprost-timolol	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Prostaglandin analog and beta-blocker combination	Beta-adrenergic receptors, Prostaglandin receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog and beta-blocker combination class)

Afyon Kocatepe University Hospital · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Travoprost and Timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/travoprost-and-timolol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab